Visa Inc (NYSE:V) has today made the much await announcement. It disclosed that it was entering a settlement agreement with Actavis Laboratories FL. The top provider has over a long period of time been strategizing on the best way forward to resolve the patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
According to some sources familiar with the matter, U.S. District Court for the District of New Jersey has since 2014 to date kept the litigation pending. The company officials have been making numerous efforts to have the U.S. Food and Drug Administration approve the market generic versions of Qsymia.
This has as a matter of been in the hope that the company would be able to sell the product freely and as a result generate high revenues. Just like any other top provider, the company has numerous plans underway that will help it rise to the top to become an industry leader.
It is a thoughtful move for any top provider to consider expanding its operations. Visa Inc now seems determined more than ever. It intends officially kick starts its operations in the selling of the generic version of Qsymia. With proper marketing strategies it hopes to control a larger market share which will see it pose high competition to most of the top related companies.
Market dynamics keep on shifting from time to time. According to Yahoo, the top provider has consistently channeled a large chunk of its resources into research in a bid to try and come up top solutions.
Providing top quality products and services has always been the major priority of the provider. One of the top executives working with it has affirmed that they won’t let anything stand between them and offering the patients the very best in terms of healthcare.
VIVUS’ Chief Executive Office, Seth H. Z. Fischer while addressing a press conference said, “We are pleased to have this litigation resolved and remain confident in the strength of our intellectual property for Qsymia and our other products and technologies. We will continue to defend our existing patents, and intend to further expand our portfolio of intellectual property as we innovate therapies that advance treatment for patients with serious unmet medical needs.”
